Marketing
Retail
Industry
GLP-1 Economics & Future of Food. What a molecule changes in the economy: patients, households and the halo of “GLP-1 friendly” consumers
Appetite is becoming a medical variable. The battle, in the aisle and at the point of sale, is being fought now.
For the first time, a class of drugs is changing appetite across an entire population. In the United States, nearly one household in four includes a GLP-1 user, and the effect on the shopping basket is now measured: −5.3% in supermarket purchases over six months, −10.1% for savory snacks, and −8% in fast food. This HUB Institute foresight report takes this shock seriously without dramatizing it. Transposed to France, where reimbursement is only a few months old and targets severe obesity, the effect remains below the market’s annual growth, even in our high-case trajectory. The GLP-1 impact is slow and aggregated.
The opportunity, however, is immediate. Nutritional density (protein, fiber, small portions) is already monetized in retail panels: €2.4 billion of functional products in France, growing seven times faster than the market. The brands that win do not claim GLP-1; they sell a promise open to everyone.
The HUB Institute’s conviction comes down to one line: encourage food industry players to position themselves now on nutritional density, within the framework Europe allows, and without waiting for the wave.
community.content.publishedatNovember 13, 2026
This report is reserved for HUB Institute members.
In Brief (Key Takeaways)
1GLP-1’s impact on the shopping basket is slow and aggregated.
2Nutritional density is already monetized: €2.4bn of functional food in France.
3Winning brands don’t claim GLP-1; they sell a promise open to everyone.
